Compare JPMorgan Chase & Co (JPM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Natera Inc. Common Stock — how do they compare? JPMorgan Chase & Co trades at $337.2 (market cap $880.15B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: JPMorgan Chase & Co is far larger — about 15.4× Natera Inc. Common Stock's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Natera Inc. Common Stock for 0 Days on average.
| JPM | NTRA | |
|---|---|---|
Market Cap | $880.15B | $57.03B |
Volume | 13,756,367 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $365.18 | $425.64 |
52-Week Low | $282.84 | $179.42 |
Typical Hold Time | 127 Days | 0 Days |
Enterprise Value | $1.40T | $56.18B |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $335.28, up 0.29% with a bearish technical signal despite strong fundamentals. The company reported revenue of $181.85B in 2025 with net income of $57.05B, maintaining solid profitability metrics including 33.38% net margin and 18.43% ROE. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q3 miss, while analysts maintain a Moderate Buy consensus with $371.91 price target.
The stock offers value with a 13.9 P/E ratio and strong institutional support, though negative cash flow trends and geopolitical risks present headwinds. Technical resistance at $336-337 levels and bearish moving averages suggest near-term consolidation, while fundamental strength supports long-term growth potential.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
